Compare IOP Reduction

15 products »

close Created with Sketch.

Simbrinza

Alcon, a Novartis Division

Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

At-a-Glance
  • Mechanism of Action: Brinzolamide inhibits carbonic anhydrase in the ciliary processes of the eye to decrease aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Brinzolamide has a peak ocular hypotensive effect occurring at 2 to 3 hours post-dosing. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. Brimonidine tartrate has a peak ocular hypotensive effect occurring at two hours post-dosing. The result is a reduction in intraocular pressure (IOP).
  • Dosage: One drop in the affected eye(s) three times daily

Details

FDA

Yes

CE Mark

Not specified

Active Ingredients

Brinzolamide/brimonidine tartrate

Application

Topical

Status

Prescription

Strength

1%/0.2%

Company Information

Contact the company for additional information, availability, or pricing:

Alcon, a Novartis Division

alcon.com

6201 South Freeway

Fort Worth, TX 76134